Pretransplantation C-peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1, 2011, Pages 86-92

  Griffith, Michelle L ^a   Jagasia, Madan H ^a   Misfeldt, Amanda A ^a   Chen, Heidi ^a   Engelhardt, Brian G ^a   Kassim, Adetola ^a   Savani, Bipin N ^a   Survant, Margaret ^a   Jagasia, Shubhada M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Metabolic complications

Indexed keywords

BUSULFAN; C PEPTIDE; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OVERALL SURVIVAL; POSTTRANSPLANTATION DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; ALLOTRANSPLANTATION; BLOOD; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFLAMMATION; INSULIN RESISTANCE; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; RISK FACTOR; SURVIVAL RATE; TIME;

ADULT; C-PEPTIDE; DIABETES MELLITUS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 79956191588     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.06.010     Document Type: Article

References (20)

1. Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;110:3463-3471.
2. Tichelli A, Passweg J, Wojcik D, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93:1203-1210.
3. Abou-Mourad YR, Lau BC, Barnett MJ, et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone MarrowTransplant. 2010;45: 295-302.
4. Baker KS, Gurney JG, Ness KK, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood. 2004;104:1898-1906.
5. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplantation Survivor Study. Blood. 2007;109:1765-1772.
6. Majhail NS, Challa TR, Mulrooney DA, et al. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15:1100-1107.
7. Annaloro C, Usardi P, Airaghi L, et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:797-804.
8. Majhail NS, Flowers ME, Ness KK, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2009;43:49-54.
9. Taskinen M, Saarinen-Pihkala UM, Hovi L, et al. Impaired glucose tolerance and dyslipidaemia as late effects after bonemarrow transplantation in childhood. Lancet. 2000;356:993-997.
10. Subramanian S, Trence DL. Immunosuppressive agents: effects on glucose and lipid metabolism. Endocrinol Metab Clin North Am. 2007;36:891-905.
11. Haffner S, Miettinen H, Stern M. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997;20:1087-1092.
12. Shehab-Eldin W, Shoker A. Predictors of new onset of diabetes after transplantation in stable renal recipients. Nephron Clin Pract. 2008;110:c1-c9.
13. Ramesh Prasad GV, Huang M, Bandukwala F, et al. Pretransplantation glucose testing for predicting new-onset diabetes mellitus after renal transplantation. Clin Nephrol. 2009;71:140-146.
14. Saliba F, Lakehal M, Pageaux GP, et al. Risk factors for newonset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl. 2007;13:136-144.
15. Hammer MJ, Casper C, Gooley TA, et al. The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2009;15: 344-351.
16. Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009;15:930-939.
17. + effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15:914-920.
18. Engelhardt BG, Jagasia M, Savani BN, et al. Regulatory T cell expression of CLA or α4b7 and skin or gut acute graft-versushost disease outcomes. Bone Marrow Transplant. 2010. in press.
19. Vela-Ojeda J, Montiel-Cervantes L, Granados-Lara P, et al. Role of CD4+CD25+(high)Foxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation. Stem Cells Dev. 2010;19:333-340.
20. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Proceedings of an International Expert Panel meeting, Barcelona, Spain, February 19, 2003. Transplantation. 2003;75: SS3-S24.